Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | Advances in PSMA radioligand therapy for mCRPC

Tobias Maurer, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany talks on the use of radioligand therapy for treatment of metastatic castration-resistant prostate cancer (mCRPC). Though an effective, well-tolerated and safe treatment in patients with later-stage mCRPC, Dr Maurer comments on issues relating to the availability of radiochemicals and trained personnel to deliver this form of therapy. Moreover, Dr Maurer discusses the future use of PSMA radioligand therapy, such as for the early treatment of prostate cancer, as investigated in the Phase I/II LuTectomy trial (NCT04430192). This interview took place at the European Association of Urology (EAU) Meeting 2022.

Disclosures

Dr Maurer reports the following conflicts of interest:
Advisory roles: Advanced Accelerator Applications International S.A., Novartis, Telix, ROTOP Pharma, GEMoAb, Astellas, Blue Earth Diagnostics, ABX
Speaker roles for Bayer, Sanofi-Aventis, Astellas, Phillips